Cost-effectiveness of treatment with etanercept for psoriasis in Sweden

被引：0
|
作者：
Christopher Knight
Josephine Mauskopf
Mats Ekelund
Amitabh Singh
Shiyi Yang
Robert Boggs
机构：
[1] RTI Health Solutions,
[2] Velocity House Business and Conference Centre,undefined
[3] RTI Health Solutions,undefined
[4] Pfizer Inc.,undefined
[5] Pfizer Inc.,undefined
来源：
The European Journal of Health Economics | 2012年 / 13卷
关键词：
Cost-effectiveness; Psoriasis; Etanercept; Adalimumab; Intermittent treatment; QALY; I19;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：145 / 156
页数：11
相关论文
共 50 条
  • [1] Cost-effectiveness of treatment with etanercept for psoriasis in Sweden
    Knight, Christopher
    Mauskopf, Josephine
    Ekelund, Mats
    Singh, Amitabh
    Yang, Shiyi
    Boggs, Robert
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (02): : 145 - 156
  • [2] A COST-EFFECTIVENESS ANALYSIS OF ETANERCEPT FOR THE TREATMENT OF MODERATE AND SEVERE PSORIASIS IN MEXICO
    Vargas-Valencia, J.
    Sotelo-Guzman, M.
    Mould-Quevedo, J. F.
    Mucino-Ortega, E.
    Galindo-Suarez, R. M.
    [J]. VALUE IN HEALTH, 2011, 14 (03) : A55 - A55
  • [3] COST-EFFECTIVENESS OF USTEKINUMAB VS ETANERCEPT FOR SEVERE PSORIASIS
    Sura, M.
    Avxentyeva, M.
    Omelyanovsky, V
    Zorin, N.
    Hailov, P.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A506 - A506
  • [4] Cost-effectiveness of the treatment for moderate to severe psoriasis in Mexico:: Infliximab, etanercept and efalizumab
    Mucino, E.
    Rivas, R.
    Zapata, L.
    [J]. VALUE IN HEALTH, 2008, 11 (03) : A288 - A288
  • [5] THE COST-EFFECTIVENESS OF HYPERTENSION TREATMENT IN SWEDEN
    JOHANNESSON, M
    [J]. PHARMACOECONOMICS, 1995, 7 (03) : 242 - 250
  • [6] COST-EFFECTIVENESS OF ETANERCEPT AND EFALIZUMAB IN THE MANAGEMENT OF MODERATE AND SEVERE PLAQUE PSORIASIS
    Ortonne, J. P.
    Feneron, D.
    Daures, J. P.
    Ollivier, A. L.
    Thiriet, C.
    Maurel, F.
    Le Pen, C.
    [J]. VALUE IN HEALTH, 2008, 11 (06) : A617 - A617
  • [7] COST EFFECTIVENESS OF TREATMENT WITH ETANERCEPT OR USTEKINUMAB FOR MODERATE TO SEVERE PSORIASIS
    Villacorta, R.
    Hay, J.
    Messali, A.
    [J]. VALUE IN HEALTH, 2012, 15 (04) : A103 - A103
  • [8] COST-EFFECTIVENESS OF COMPLYING WITH TREATMENT GUIDELINES IN SWEDEN
    Jonsson, E.
    Hansson-Hedblom, A.
    Ljunggren, O.
    Akesson, K.
    Spangeus, A.
    Borgstrom, F.
    Kanis, J. A.
    [J]. OSTEOPOROSIS INTERNATIONAL, 2017, 28 : S440 - S440
  • [9] COST-EFFECTIVENESS OF USTEKINUMAB IN THE TREATMENT OF PSORIASIS IN FINLAND
    Vaatainen, S.
    Soini, E. J.
    Valgardsson, V. S.
    Malkonen, T.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A670 - A670
  • [10] Cost-effectiveness of secukinumab compared with ustekinumab and etanercept for the treatment of moderate-to-severe plaque psoriasis in Greece
    Tzanetakos, C.
    Kourlaba, G.
    Hatzikou, M.
    Antoniou, C.
    Ioannides, D.
    Lefaki, I.
    Petridis, A.
    Rigopoulos, D.
    Roussaki-Schulze, V.
    Sotiriadis, D.
    Maniadakis, N.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2016, 30 : 61 - 62
12345